Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
pharmaphorum4d
New Vertex drugs could help 90% of cystic fibrosis patients
Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...
The Motley Fool on MSN21d
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Cystic Fibrosis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the safety, and tolerability and efficacy ...
University of California11d
Breathing new life: Working toward an inhalable gene therapy for cystic fibrosis
Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price
Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...
Vertex Announces Medsafe Consent For TRIKAFTA®To Treat Children With Cystic Fibrosis Ages 2-5 Years
Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of TRIKAFTA® ...
Scoop12d
Vertex Announces Medsafe Consent For TRIKAFTA®To Treat Children With Cystic Fibrosis Ages 2-5 Years
Vertex Pharmaceuticals today announced that ... for the treatment of cystic fibrosis to include children aged 2-5 years who have at least one F508del mutation in the cystic fibrosis transmembrane ...